This page shows the latest Sarepta news and features for those working in and with pharma, biotech and healthcare.
LGMD). Søren Tulstrup, president and chief executive officer of Hansa, said: "We are very excited about the results we have seen in the preclinical phase of our collaboration with Sarepta. ... Sarepta submitted a Biologics License Application to the US
Sarepta Therapeutics has announced its intent to submit a Biologics License Application (BLA) to accelerate approval for SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant patients with Duchenne muscular dystrophy ... Doug Ingram,
Sarepta Therapeutics has revealed some early promising data for its Duchenne muscular dystrophy (DMD), although the company also reported serious adverse events associated with the treatment. ... Although Sarepta did not identify any new safety signals
Sarepta is also prominent in the DMD therapy area and the company's second approved DMD therapy Vyondys 53 (golodirsen) received approval last December. ... Vyondys 53 is Sarepta’s second approved DMD therapy after Exondys 51 (eteplirsen).
The Roche deal is Dyno’s third pharma collaboration, in addition to its existing partnerships with Novartis and Sarepta Therapeutics. ... disease. The Sarepta deal is focused on the development of new AAV vectors for gene therapies aimed at targeting
The approval will see Viltepso enter a competitive market and likely head into a rivalry with Sarepta’s Vyondys 53 (golodirsen), which gained FDA approval last December.. ... Like NS Pharma, Sarepta is conducting a confirmatory trial of Vyondys 53
More from news
Approximately 21 fully matching, plus 27 partially matching documents found.
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
A gene therapy, and Duchenne pioneer Sarepta.
Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.
The licence deal obtained by Summit from Sarepta for a phase II product had an even lower upfront, 7% of the total consideration. ... 767. Sarepta (US). Summit (UK). Licence collaboration. Europe Utrophin modulator pipeline, lead molecule phase II for
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at Sarepta Therapeutics.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...